← Leaderboards
Silvija I Staprans
University Of California San Francisco
$7,069,069
Attributed
$7,069,069
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–08$2M$1.5M$1M$500K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$7,069,069 · 13
By mechanism
R01$3,173,458 · 2
U19$2,171,261 · 1
P51$898,551 · 8
R21$800,000 · 1
M01$25,799 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Judith Ann Aberg$20,303,532
- Karin L Gaensler$8,072,507
Others in their field
Top investigators on “T Lymphocyte”
- Barton F Haynes · Duke University$408,040,925
- Lawrence Corey · Fred Hutchinson Cancer Center$299,247,526
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$157,640,776
- Dan H. Barouch · Fred Hutchinson Cancer Center$139,062,963
- James Dennis Neaton · Northwestern University$107,288,548
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
Research focus
T LymphocyteSimian Immunodeficiency VirusLeukocyte Activation /TransformationMacaca MulattaVirus ReplicationHiv InfectionsActive ImmunizationHuman SubjectImmune ResponseClinical ResearchResourcesMumps VirusHuman Immunodeficiency Virus 1Model Design /DevelopmentFundingInfectionCytokineChild (0-11)RubivirusMeasles VaccineViral VaccinesImmunePhenotypeResponse
Grant awards (29)
Optimizing Routes of Vaccine Delivery$256,288
U19 · FY2008 · AI · contact PI
HOST SPECIFIC RESPONSES IN SIV-INDUCED HEMATOSUPPRESSION$81,625
P51 · FY2008 · RR · contact PI
Optimizing Routes of Vaccine Delivery$409,302
U19 · FY2007 · AI · contact PI
HOST SPECIFIC RESPONSES IN SIV-INDUCED HEMATOSUPPRESSION$78,544
P51 · FY2007 · RR · contact PI
DEVELOPMENT OF A LOW INOCULUM SHIV CHALLENGE MODEL$65,453
P51 · FY2007 · RR · contact PI
Optimizing Routes of Vaccine Delivery$439,495
U19 · FY2006 · AI · contact PI
DEVELOPMENT OF A LOW INOCULUM SHIV CHALLENGE MODEL$59,665
P51 · FY2006 · RR · contact PI
HOST SPECIFIC RESPONSES IN SIV-INDUCED HEMATOSUPPRESSION$59,665
P51 · FY2006 · RR · contact PI
Host specific responses in SIV-induced hematosuppression$1
R01 · FY2006 · HL · contact PI
Host specific responses in SIV-induced hematosuppression$716,654
R01 · FY2005 · HL
Optimizing Routes of Vaccine Delivery$537,491
U19 · FY2005 · AI
HOST SPECIFIC RESPONSES IN SIV-INDUCED HEMATOSUPPRESSION$52,438
P51 · FY2005 · RR
DEVELOPMENT OF A LOW INOCULUM SHIV CHALLENGE MODEL$52,438
P51 · FY2005 · RR
Cellular Immune Responses and AIDS Pathogenesis$864,093
R01 · FY2004 · AI
Host specific responses in SIV-induced hematosuppression$833,393
R01 · FY2004 · HL
Optimizing Routes of Vaccine Delivery$528,685
U19 · FY2004 · AI
Development of a low inoculum SHIV challenge model$400,000
R21 · FY2004 · AI
DETERMINANTS OF NON PATHOGENIC SIV INFECTION$51,707
P51 · FY2004 · RR
DEVELOPMENT OF A LOW INOCULUM SHIV CHALLENGE MODEL$51,707
P51 · FY2004 · RR
HOST SPECIFIC RESPONSES IN SIV-INDUCED HEMATOSUPPRESSION$51,707
P51 · FY2004 · RR
Host specific responses in SIV-induced hematosuppression$759,317
R01 · FY2003 · HL
Development of a low inoculum SHIV challenge model$400,000
R21 · FY2003 · AI
DETERMINANTS OF NON PATHOGENIC SIV INFECTION$209,143
P51 · FY2002 · RR
EFFECTS OF PEDIATRIC MEASLES/MUMPS/RUBELLA VACCINE ON HIV 1 REPLICATION$0
M01 · FY2002 · RR
EFFECTS OF PEDIATRIC MEASLES/MUMPS/RUBELLA VACCINE ON HIV 1 REPLICATION$0
M01 · FY2001 · RR
DETERMINANTS OF NON PATHOGENIC SIV INFECTION$84,459
P51 · FY2000 · RR
EFFECTS OF PEDIATRIC MEASLES/MUMPS/RUBELLA VACCINE ON HIV 1 REPLICATION$25,799
M01 · FY2000 · RR
EFFECTS OF PEDIATRIC MEASLES/MUMPS/RUBELLA VACCINE ON HIV 1 REPLICATION$0
M01 · FY2000 · RR
EFFECTS OF PEDIATRIC MEASLES/MUMPS/RUBELLA VACCINE ON HIV 1 REPLICATION$0
M01 · FY2000 · RR